EN DE
Watch Prime Medicine, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Prime Medicine, Inc. (PRME) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Prime Medicine, Inc. stock $1.98, price $4.19, that is 52.7% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US74168J1016

PM Prime Medicine, Inc. logo Thin data Nov 15, 2026

Prime Medicine, Inc.

PRME · US

Far too expensive (fair value 53% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Recent news mostly positive 
Fair value $1.98 · Strongly overvalued 
Quality 29/100 
Weak Growth (revenue 5y −2.3 %/yr in USD) 
Negative free cash flow 
Trails peers (1/6) 
Narrow moat 7/100
Thin data 
Estimate
Watch Prime Medicine, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.12 $1.15 Fair Value $1.98 Oct 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

49‑month range $1.15 – $21.12 · fair‑value band $1.48 – $2.47 · the $4.19 price screens above the $1.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Prime Medicine in your weekly email

Every Wednesday you see whether Prime Medicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.

Show moreShow less

Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.

The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.

In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.

The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Prime Medicine, Inc. (PRME) currently trades at $4.19, while our estimate is $1.98, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.48 (bear) to $2.47 (bull), the price of $4.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Prime Medicine, Inc. reported revenue of $4.6M in FY2025 versus $0 in FY2021. Reported net income was −$201M in FY2025.

Key figures

Market cap $932M Small · EPS (TTM) $−0.9700 · Return on equity −207% · Return on assets (EBIT) −59.0% (5-year average) · Operating margin −2,584% · Revenue (TTM) $7.1M · Revenue growth (YoY) +244% · Free cash flow −$167M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).

What moves the price

The share trades about 22% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −53%, PRME screens richer than that median.

Fair Value

Bear $1.48 Fair Value $1.98 Bull $2.47
Price $4.19 · Downside -52.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 59
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+55.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.9% (2020) → −4,498.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PRME screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Prime Medicine, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −52.7% · Bottom 25%
Profitability
Return on assets −58.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 243.9% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs PRME
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs PRME
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs PRME
argenx SE ARGX $950.95 $908.40 −4% vs PRME
CSL Limited CSL A$199.55 A$186.49 −7% vs PRME
Moderna, Inc MRNA $215.27 $135.64 −37% vs PRME
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs PRME
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs PRME
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs PRME
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs PRME

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prime Medicine, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Prime Medicine, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/PRME

Frequently asked questions

Is Prime Medicine, Inc. (PRME) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $1.98 versus a price of $4.19, about 53% lower (overvalued).
What is the fair value of PRME?
Our estimate for Prime Medicine, Inc. is $1.98 (as of Nov 15, 2026), built from audited fundamentals. The current price: $4.19.
What is the quality score of PRME?
Prime Medicine, Inc. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prime Medicine, Inc. (PRME)?
Our calculated price target is the estimate of $1.98 (as of Nov 15, 2026). Cautious scenario $1.48, optimistic scenario $2.47. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Prime Medicine, Inc. stock forecast for 2026?
Our estimate puts fair value at $1.98, about 53% lower versus a price of $4.19 (overvalued). Cautious scenario $1.48, optimistic scenario $2.47. The calculation is refreshed regularly with new filings.
What is the revenue of Prime Medicine, Inc. (PRME)?
Prime Medicine, Inc. reported trailing-twelve-month revenue of about $7.1M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Prime Medicine, Inc. (PRME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prime Medicine, Inc. it is $1.98 per share (as of Nov 15, 2026), against a price of $4.19.
Is Prime Medicine, Inc. stock overvalued or undervalued in 2026?
As of Nov 15, 2026, PRME trades above its calculated fair value: price $4.19, fair value $1.98, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRME?
No. The price is what the market pays today ($4.19); the fair value is what the company's own numbers justify ($1.98). For Prime Medicine, Inc. the two are $2.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prime Medicine, Inc. worth?
The market values Prime Medicine, Inc. at about $932M (market capitalisation, as of Nov 15, 2026). Per share that is $4.19; our models calculate a fair value of $1.98 per share.
What do the bullish and bearish scenarios say about PRME?
Our models span a range for Prime Medicine, Inc.: cautious scenario $1.48, base $1.98, optimistic $2.47 per share (as of Nov 15, 2026, price $4.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Prime Medicine, Inc. (PRME)?
Balance-sheet figures for Prime Medicine, Inc. (as of Nov 15, 2026): return on equity −207.2%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is PRME from its 52-week high?
Prime Medicine, Inc. trades at $4.19, about 22% below its 52-week high of $5.36 and 55% above the low of $2.70 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.98 is for.
Which stocks are comparable to Prime Medicine, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prime Medicine, Inc. stock attractive at the current price?
The data as of Nov 15, 2026: price $4.19, calculated fair value $1.98 (−53%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Prime Medicine, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prime Medicine, Inc. (PRME)?
The closing price on Nov 16, 2026 was $4.19. Our estimate is $1.98, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prime Medicine, Inc. right now?
The price sits above even our optimistic bull case ($2.47). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Prime Medicine, Inc.

How large is the market capitalisation of Prime Medicine, Inc. (PRME)?
The market capitalisation of Prime Medicine, Inc. is $932M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Prime Medicine, Inc. (PRME)?
Earnings per share at Prime Medicine, Inc. are $−0.9700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Prime Medicine, Inc. (PRME)?
The return on equity (ROE) of Prime Medicine, Inc. is −207% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prime Medicine, Inc. (PRME)?
On an EBIT basis the return on assets of Prime Medicine, Inc. is −59.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prime Medicine, Inc. (PRME)?
The operating margin of Prime Medicine, Inc. is −2,584% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prime Medicine, Inc. (PRME)?
Revenue at Prime Medicine, Inc. is growing 244% versus a year earlier (3y avg −3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prime Medicine, Inc. (PRME) generate?
The free cash flow of Prime Medicine, Inc. is −$167M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Prime Medicine, Inc. (PRME) carry?
The net debt of Prime Medicine, Inc. is $53.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Prime Medicine, Inc. in the live analysis

One click puts Prime Medicine, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.